MARKET

PMXSF

PMXSF

Syntara Ltd
OTCPK
0.065
NaN%
Closed 09:30 12/04 EST
OPEN
--
PREV CLOSE
0.065
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.078
52 WEEK LOW
0.065
MARKET CAP
106.11M
P/E (TTM)
-18.5714
1D
5D
1M
3M
1Y
5Y
1D
No Data
About PMXSF
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Webull offers Syntara Ltd stock information, including OTCPK: PMXSF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMXSF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMXSF stock methods without spending real money on the virtual paper trading platform.